157 related articles for article (PubMed ID: 26529585)
1. Reversal effects of Raloxifene on paclitaxel resistance in 2 MDR breast cancer cells.
Xu L; Lei J; Jiang D; Zhou L; Wang S; Fan W
Cancer Biol Ther; 2015; 16(12):1794-801. PubMed ID: 26529585
[TBL] [Abstract][Full Text] [Related]
2. [The role of mitogen-activated protein kinase cascades in inhibition of proliferation in human prostate carcinoma cells by raloxifene: an in vitro experiment].
Zhang YX; Kong CZ
Zhonghua Yi Xue Za Zhi; 2008 Jan; 88(4):271-5. PubMed ID: 18361842
[TBL] [Abstract][Full Text] [Related]
3. Apoptotic action of 17beta-estradiol in raloxifene-resistant MCF-7 cells in vitro and in vivo.
Liu H; Lee ES; Gajdos C; Pearce ST; Chen B; Osipo C; Loweth J; McKian K; De Los Reyes A; Wing L; Jordan VC
J Natl Cancer Inst; 2003 Nov; 95(21):1586-97. PubMed ID: 14600091
[TBL] [Abstract][Full Text] [Related]
4. Establishment of paclitaxel-resistant breast cancer cell line and nude mice models, and underlying multidrug resistance mechanisms in vitro and in vivo.
Chen SY; Hu SS; Dong Q; Cai JX; Zhang WP; Sun JY; Wang TT; Xie J; He HR; Xing JF; Lu J; Dong YL
Asian Pac J Cancer Prev; 2013; 14(10):6135-40. PubMed ID: 24289639
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of JAK2 Reverses Paclitaxel Resistance in Human Ovarian Cancer Cells.
Xu Y; Zhang J; Wu J; Zhong S; Li H
Int J Gynecol Cancer; 2015 Nov; 25(9):1557-64. PubMed ID: 26360705
[TBL] [Abstract][Full Text] [Related]
6. Reversal of Chemoresistance in Ovarian Cancer by Co-Delivery of a P-Glycoprotein Inhibitor and Paclitaxel in a Liposomal Platform.
Zhang Y; Sriraman SK; Kenny HA; Luther E; Torchilin V; Lengyel E
Mol Cancer Ther; 2016 Oct; 15(10):2282-2293. PubMed ID: 27466355
[TBL] [Abstract][Full Text] [Related]
7. Estrogen receptor α attenuates therapeutic efficacy of paclitaxel on breast xenograft tumors.
Chang J; Sui M; Fan W
Breast Cancer Res Treat; 2012 Aug; 134(3):969-80. PubMed ID: 22374518
[TBL] [Abstract][Full Text] [Related]
8. CKT0353, a novel microtubule targeting agent, overcomes paclitaxel induced resistance in cancer cells.
Dinić J; Ríos-Luci C; Karpaviciene I; Cikotiene I; Fernandes MX; Pešić M; Padrón JM
Invest New Drugs; 2020 Jun; 38(3):584-598. PubMed ID: 31177401
[TBL] [Abstract][Full Text] [Related]
9. The role of P-glycoprotein/cellular prion protein interaction in multidrug-resistant breast cancer cells treated with paclitaxel.
Li QQ; Cao XX; Xu JD; Chen Q; Wang WJ; Tang F; Chen ZQ; Liu XP; Xu ZD
Cell Mol Life Sci; 2009 Feb; 66(3):504-15. PubMed ID: 19099191
[TBL] [Abstract][Full Text] [Related]
10. Hypoxia decreased chemosensitivity of breast cancer cell line MCF-7 to paclitaxel through cyclin B1.
Dong XL; Xu PF; Miao C; Fu ZY; Li QP; Tang PY; Wang T
Biomed Pharmacother; 2012 Feb; 66(1):70-5. PubMed ID: 22264882
[TBL] [Abstract][Full Text] [Related]
11. Quinoline derivative KB3-1 potentiates paclitaxel induced cytotoxicity and cycle arrest via multidrug resistance reversal in MES-SA/DX5 cancer cells.
Koo JS; Choi WC; Rhee YH; Lee HJ; Lee EO; Ahn KS; Bae HS; Ahn KS; Kang JM; Choi SU; Kim MO; Lu J; Kim SH
Life Sci; 2008 Nov; 83(21-22):700-8. PubMed ID: 18845169
[TBL] [Abstract][Full Text] [Related]
12. Fulvestrant, a selective estrogen receptor down-regulator, sensitizes estrogen receptor negative breast tumors to chemotherapy.
Jiang D; Huang Y; Han N; Xu M; Xu L; Zhou L; Wang S; Fan W
Cancer Lett; 2014 May; 346(2):292-9. PubMed ID: 24462822
[TBL] [Abstract][Full Text] [Related]
13. Taxol-induced growth arrest and apoptosis is associated with the upregulation of the Cdk inhibitor, p21WAF1/CIP1, in human breast cancer cells.
Choi YH; Yoo YH
Oncol Rep; 2012 Dec; 28(6):2163-9. PubMed ID: 23023313
[TBL] [Abstract][Full Text] [Related]
14. Cosilencing of PKM-2 and MDR-1 Sensitizes Multidrug-Resistant Ovarian Cancer Cells to Paclitaxel in a Murine Model of Ovarian Cancer.
Talekar M; Ouyang Q; Goldberg MS; Amiji MM
Mol Cancer Ther; 2015 Jul; 14(7):1521-31. PubMed ID: 25964202
[TBL] [Abstract][Full Text] [Related]
15. Estrogen receptor alpha mediates breast cancer cell resistance to paclitaxel through inhibition of apoptotic cell death.
Sui M; Huang Y; Park BH; Davidson NE; Fan W
Cancer Res; 2007 Jun; 67(11):5337-44. PubMed ID: 17545614
[TBL] [Abstract][Full Text] [Related]
16. Co-expression of several molecular mechanisms of multidrug resistance and their significance for paclitaxel cytotoxicity in human AML HL-60 cells.
Huang Y; Ibrado AM; Reed JC; Bullock G; Ray S; Tang C; Bhalla K
Leukemia; 1997 Feb; 11(2):253-7. PubMed ID: 9009089
[TBL] [Abstract][Full Text] [Related]
17. Loss of PKCδ Induces Prostate Cancer Resistance to Paclitaxel through Activation of Wnt/β-Catenin Pathway and Mcl-1 Accumulation.
Flores ML; Castilla C; Gasca J; Medina R; Pérez-Valderrama B; Romero F; Japón MA; Sáez C
Mol Cancer Ther; 2016 Jul; 15(7):1713-25. PubMed ID: 27196755
[TBL] [Abstract][Full Text] [Related]
18. Apoptosis induction in human breast cancer cell lines by synergic effect of raloxifene and resveratrol through increasing proapoptotic genes.
Mirzapur P; Khazaei MR; Moradi MT; Khazaei M
Life Sci; 2018 Jul; 205():45-53. PubMed ID: 29705353
[TBL] [Abstract][Full Text] [Related]
19. 5-(3,4,5-trimethoxybenzoyl)-4-methyl-2-(p-tolyl) imidazol (BZML) targets tubulin and DNA to induce anticancer activity and overcome multidrug resistance in colorectal cancer cells.
Bai Z; Liu X; Guan Q; Ding N; Wei Q; Tong B; Zhao M; Zhang W; Ma L
Chem Biol Interact; 2020 Jan; 315():108886. PubMed ID: 31682804
[TBL] [Abstract][Full Text] [Related]
20. Tissue inhibitor of metalloproteinase-1 protects MCF-7 breast cancer cells from paclitaxel-induced apoptosis by decreasing the stability of cyclin B1.
Wang T; Lv JH; Zhang XF; Li CJ; Han X; Sun YJ
Int J Cancer; 2010 Jan; 126(2):362-70. PubMed ID: 19609944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
